Article Text

other Versions

PDF
Lung cancer tissue diagnosis in poor lung function: addressing the ongoing percutaneous lung biopsy FEV1 paradox using Heimlich valve
  1. R Abdullah1,
  2. A N Tavare2,
  3. A Creamer1,
  4. D Creer1,
  5. R Vancheeswaran1,
  6. S S Hare2
  1. 1Department of Respiratory Medicine, Barnet General Hospital, Royal Free London NHS Foundation Trust, London, UK
  2. 2Department of Radiology, Barnet General Hospital, Royal Free London NHS Foundation Trust, London, UK
  1. Correspondence to Dr Samanjit S Hare, Department of Radiology, Barnet Hospital, Royal Free London NHS Foundation Trust, Wellhouse Lane, EN5 3DJ, UK; samhare{at}nhs.net

Abstract

Many centres continue to decline percutaneous lung biopsy (PLB) in patients with poor lung function (particularly FEV1 <1 L) due to the theoretically increased risk of pneumothorax. This practice limits access to novel lung cancer therapies and minimally invasive surgical techniques. Our retrospective single-centre analysis of 212 patients undergoing PLB, all performed prospectively and blinded to lung function, demonstrates that using ambulatory Heimlich valve chest drain (HVCD) to treat significant postbiopsy pneumothorax facilitates safe, diagnostic, early discharge lung biopsy irrespective of lung function with neither FEV1 <1 L nor transfer coefficient for carbon monoxide (TLCO) <40% predicted shown to be independent predictors of HVCD insertion or pneumothorax outcomes. Incorporating ambulatory HVCD into standard PLB practice thereby elegantly bridges the gap that currently exists between tissue diagnosis in patients with poor lung function and the advanced therapeutic options available for this cohort.

  • Lung Cancer

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.